Related Experiment Video
Updated: Jan 28, 2026

Single Port Donor Nephrectomy
Published on: March 12, 2011
Donor lymphocyte infusion combined with azacitidine after allogeneic HSCT in pediatric AML: a single-center
Ana Maria Bica1,2, Andra Daniela Marcu1,2, Cristina Georgiana Jercan1,2
1Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.
Introduction:
Donor lymphocyte infusion (DLI) can enhance graft-versus-leukemia (GvL) effects following allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric acute myeloid leukemia (AML). However, the optimal integration of azacitidine (Aza) with DLI in children remains uncertain.
Methods:
We retrospectively analyzed 16 pediatric AML patients (≤18 years) treated at Fundeni Clinical Institute between 2016 and 2024 who received DLI in combination with azacitidine (75 mg/m2/day for 7 days every 4 weeks) after HSCT. DLI was administered prophylactically or preemptively based on mixed donor chimerism (MDC), measurable residual disease (MRD) positivity, or high-risk cytogenetics, or therapeutically for post-transplant relapse, with or without chemotherapy. Outcomes assessed included overall survival (OS), donor chimerism, relapse rate, and graft-versus-host disease (GVHD).
Results:
After a median follow-up of 46.5 months, five patients received prophylactic/preemptive DLI and eleven received therapeutic DLI (seven with chemotherapy, four without). All patients in the prophylactic/preemptive group achieved full donor chimerism and MRD negativity, with an OS of 80% at 2.7 years. In the therapeutic group, median OS was 23.8 months with chemotherapy and 13.8 months without. OS differences between groups were not statistically significant (p = 0.384). Acute GVHD occurred in two patients (12.5%) in the therapeutic + chemotherapy subgroup; no chronic GVHD or non-relapse mortality was observed.
Conclusion:
Azacitidine combined with DLI is feasible and safe in pediatric AML after HSCT, particularly when applied prophylactically or preemptively to restore donor chimerism or eradicate MRD. Therapeutic use in overt relapse remains challenging and provides limited benefit. Prospective multicenter studies are needed to define optimal timing, dosing, and combination strategies for integrating azacitidine with DLI in this high-risk pediatric population.
More Related Videos
Related Concept Videos
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Center of Gravity
Center of Gravity
To determine its location, the principle of moments can be utilized by dividing the object into...
Center of Mass
The knowledge of the center of mass can also help us to describe and predict the motion of objects. For example, when a ball is thrown...
Instantaneous Center of Zero Velocity
To analyze this, consider two points on the wheel: point A and point B. The absolute velocity of point B can be expressed as the vector sum of the absolute velocity of point A and the relative velocity of point B with respect to point A. To simplify this analysis,...
Patient-centered Care

